DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1914)

Opioid Addiction | Unmet Need | Detailed, Expanded Analysis (US/EU)

Opioid Addiction | Unmet Need | Detailed, Expanded Analysis (US/EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone, buprenorphine, and buprenorphine / naloxone combination) prevent a patient from experiencing withdrawal symptoms but allow the patient to still experience a limited “high” without taking any illicit opioids. Abstinent therapies (i.e., naltrexone) block the euphoric effect of opioids if a patient attempts to take an illicit opioid. However, all of these drugs are associated with clinical shortcomings in efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. This report examines physicians’ key treatment drivers and analyzes the greatest areas of unmet treatment need and thereby the opportunities in this space.

Questions Answered

  • What are the treatment drivers and goals for opioid addiction?
  • Which drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do buprenorphine-containing therapies (e.g., Suboxone Film, Sublocade) perform on key treatment drivers and goals for opioid addiction?
  • What are the prevailing areas of unmet need and opportunity in the treatment of opioid addiction?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European psychiatrists for a hypothetical new opioid addiction drug?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European psychiatrists fielded in November 2018

Key companies: Indivior, Orexo, Braeburn Pharmaceuticals, Camurus

Key drugs: Suboxone Film, Subutex, Sublocade, Zubsolv, methadone, naltrexone

Key metrics included:

  • Target Product Profile (TPP) simulator based on conjoint analysis methodology.
  • Stated versus derived importance of product attributes on prescribing behavior.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet needs in the indication and related indications.
  • Analysis of remaining drug development opportunities.

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis (US/EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
      • Rationale for Drug Selection
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Key Findings: Stated vs. Derived Importance
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Opioid Addiction
      • Key Findings: Unmet Need in Opioid Addiction and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Opioid Addiction Market and Emerging Therapy Insights
        • Opportunity: A Novel Therapy Offering Greater Reduction in Opioid Use in Patients with Opioid Addiction
        • Opportunity: A New Therapy for Opioid Addiction with a More-Convenient Delivery Profile
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
        • Opioid Addiction Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2
    • Appendix
      • Bibliography

Already a Client? Log in to access this report.

  • Pub Date: February 2019
  • Author(s): Niyati Khetarpal, Ph.D
  • "Niyati Khetarpal  is an analyst on the Central Nervous System, Pain, and Ophthalmology team at ;In this role, she conducts extensive secondary research to analyze and forecast pharmaceutical markets, with specific expertise in patent research. Prior to joining the company, Niyati obtained her doctorate from the International Centre for Genetic Engineering and Biotechnology for her research on Dengue virus vaccines. She received the Fulbright-Nehru doctoral scholarship in 2014 for her research on Dengue and West Nile virus envelope ;

Purchase Report

Recent reports:
You may also be interested in: